For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.
Biocon Biologics and Mylan said they have launched the long-acting insulin glargine product Semglee on the US market and hope to obtain formal biosimilar status for it. Semglee was approved in June as an equivalent to Sanofi’s Lantus insulin glargine, but not as a biosimilar, owing to the regulatory pathway taken.
It has been launched at a deep discount to the reference product and arrives at a time of great pushback against high insulin prices and limited competition. Many public and private health plans have been lowering out-of-pocket costs for patients to ensure access to this essential medicine.
Available in vials and prefilled pens, Semglee is for the control of high blood sugar in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. It is not recommended for patients with diabetic ketoacidosis.
Not a Full-Fledged Biosimilar
Although considered a biosimilar in other markets, Semglee doesn’t exactly qualify as such in the United States. It was approved via a new drug application under the Hatch-Waxman Act, a pathway traditionally used for generics and some biologics, including insulins. Because insulin approvals are now governed by the Biologics Price Competition and Innovation Act (BPCIA), and have been since March 2020, Semglee is now “deemed” a biologic.
“We are proud to be the first company, following the reference product, to receive FDA approval on and launch both the vial and pen presentations of an insulin glargine treatment with an identical amino acid sequence to Sanofi's Lantus,” said Mylan CEO Heather Bresch. She estimated the potential market for Semglee at 30 million Americans.
Mylan said it aims to have Semglee declared a full-fledged biosimilar to Lantus and has filed “all necessary documentation” to the FDA under the 351(k) pathway, which is the official BPCIA route for biosimilar approval. In addition, Mylan said it “remains confident in seeking an interchangeability designation” for the product as well.
Interchangeable designations allow pharmacists to fill prescriptions with biosimilars without consulting the prescribing physician. No current biosimilars have the interchangeable designation. It has been argued that there is such a high level of comfort with the safety and efficacy profile of insulins that approved products should be treated as interchangeable with originator products. Interchangeability would also speed the uptake of competing products.
Priced for Market Acceptance
To boost market acceptance of Semglee, Mylan, which serves as Biocon Biologics’ distribution partner in the United States, is offering packages of five 3-mL Semglee pens at the wholesale price of $147.98 and 10-mL individual vials at $98.65, which it called the lowest wholesale costs for any long-acting insulin glargine on the market.
“The list price of Semglee pen is equivalent to the Lantus launch price in 2007, and the Semglee vial is listed at Lantus’ 2010 pricing,” Mylan said in a statement. The individual vial cost of Lantus has climbed from $244 in 2013 to $431 in 2019, a 77% increase, according to a Senate Finance Committee letter.
Patient assistance programs or co-pay cards may further lower the cost, the statement said.
“We believe the US market represents a great opportunity for us and expect Semglee to contribute significantly to our goal of impacting 5 million patient lives and achieving $1 billion revenue by end of [fiscal year 2022],” said Christiane Hamacher, CEO of Biocon Biologics.
Semglee was approved based on analytical, preclinical, and clinical studies that confirmed the pharmacokinetics and pharmacodynamics, efficacy, safety, and immunogenicity of Semglee in comparison with Lantus in patients with type 1 and type 2 diabetes.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.